Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Ocaratuzumab |
Synonyms | |
Therapy Description |
Ocaratuzumab (AME-133v) is a monoclonal antibody directed against CD20, which may result in antibody-dependent cell-mediated cytotoxicity and decreased tumor cell growth (PMID: 22223529, PMID: 30089638). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ocaratuzumab | AME-133v|AME133v|AME 133v|LY2469298|LY 2469298|LY-2469298 | CD20 Antibody 21 | Ocaratuzumab (AME-133v) is a monoclonal antibody directed against CD20, which may result in antibody-dependent cell-mediated cytotoxicity and decreased tumor cell growth (PMID: 22223529, PMID: 30089638). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|